newsfilter
← Latest News
GlobeNewswire·

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary